Dendritic cell vaccine increases survival in GBM

Dendritic cell vaccine increases survival in GBM

For patients with GBM, standard treatment involves surgery, radiotherapy and temozolomide.

Here, the researchers announced results of their PhaseIII trial where an autologous tumour-lysate-pulsed Dendritic Cell Vaccine ((DCVax ® -L) was added to the standard programme. In this study after surgery patients received either Temozolomide plus the vaccine, or Temozolomide plus a placebo.

When recurrence occurred all patients were allowed to have the Dendritic Cell vaccine.

The Intention to Treat (ITT) mean Overall Survival time was shown to be 23.3 months from surgery.

For patients with methylated MGMT mean Overall Survival was 34.7 months. Almost half (46.4%) survived more than three years. Of these survivors, predicted overall survival is 88.2 months.

Only 2.1 % of those treated with the DC vaccine had an adverse effect, and this level was almost identical to standard treatment rates.

Dr. Linda Liau, was the lead author of the study. She is also chair of the neurosurgery department at the David Geffen School of Medicine at UCLA.

Liau was particularly excited about the results saying, “What’s particularly impressive about these immunotherapy trials is that there seems to be a population of about 20 to 30 percent of patients who are living significantly longer than expected — the long tail of the survival curve.”

The study was done in 4 countries (Us, UK, Canada, Germany) and involved 80 sites and over 286 patients.

These first results were published in the Journal of Translational Medicine (1).

Go to: Dendritic Cell vaccines – personalised immunotherapy

* * * * * *

Reference

  1. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6

 


  Approved by the Medical Board. Click Here 


 

2020 Research
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Chris'
Newsletter

Join Chris' NewsletterSignup today for free and be the first to get notified on new updates.